

- 21 Keywords: AGG interruption, carrier screening, CGG repeat, fragile X syndrome, nanopore
- 22 sequencing **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

- Word count: 2969
- Figures: 4
- Tables: 2
- Nonstandard abbreviations: FXS, fragile X syndrome; TP-PCR, triplet-primed PCR.
- Human gene: *FMR1*, fragile X messenger ribonucleoprotein 1.

FXS carrier screening.

Introduction

 of AGG interruptions among CGG repeats is thus essential for genetic counseling, especially for FXS carriers(4).

 Owing to the severe morbidity of FXS, carrier screening, and subsequent prenatal diagnosis are still warranted for this disease until the development of effective treatments (4, 10). Although all major ethnic groups and races appear to be susceptible to FXS, and FXS carrier prevalence is high, whether FXS carrier screening should be offered to the general 74 population has long been a subject of debate $(5, 9, 11-13)$. We previously showed that population-based carrier screening is the dominant strategy for FXS intervention in East Asia (9). Recently, population-based pan-ethnic FXS carrier screening was officially endorsed by the American College of Medical Genetics and Genomics (10). Clinical interest has shifted from "whether to perform" to "how to perform" population-based FXS carrier screening. An assay to capably address this issue should be able to examine a large number of female samples with high accuracy, low cost, short turnaround time, and ease of performance. FXS genetic testing was performed using Southern blotting, a labor-intensive method that allows estimation of CGG expansion size but cannot accurately quantitate CGG repeat number and AGG interruption patterns (4). These drawbacks have been overcome with the triplet-primed PCR (TP-PCR) assay, which has become the mainstay method in clinical use, 85 with several kits, including AmplideXTM FMR1 PCR Kit (Asuragen) and Molecular Fragile X 86 PCR Kit (Biofast) commercially available (4, 14). Typing AGG interruptions at the allelic level in female samples with TP-PCR remains challenging. Long-read sequencing-based assays for FXS genetic testing using Nanopore and PacBio sequencing have recently been developed (15-19). Theoretically, with the ability to directly sequence entire CGG repeats

AMPLIFICATION OF *FMR1* **ALLELES**

- The CGG repeats and flanking sequences of *FMR1* were amplified using a T100 Thermal
- Cycler (Bio-Rad, Hercules, CA, USA). A 50-µL reaction containing 1× Expand Long
- Template buffer 2 (Roche Diagnostics, Mannhei, Germany), 3.75U Expand Long Template
- Enzyme mix (Roche Diagnostics, Mannhei, Germany), 0.5 mmol/L dNTPs (Takara, Kyoto,
- Japan), 2.2 mol/L Betaine (SIGMA-Aldrich, Saint Louis, Missouri, USA), 0.33 mmol/L of
- each forward and reverse primer (Sangon, Shanghai, China), and 50 ng DNA template. Primer
- information and amplification conditions are listed in Supplemental Tables 2 and 3,
- respectively. After amplification, PCR products were purified with a TIANquick Midi
- 121 Purification Kit (TIANGEN, Beijing, China) and subsequently quantified with a Oubit[™]
- 122 dsDNA HS Assay Kit (Invitrogen, Carlsbad, CA, USA) on a Qubit™ fluorometer
- (ThermoFisher Scientific, Waltham, Massachusetts, USA) according to the respective
- manufacturers' instructions.

LIBRARY PREPARATION AND NANOPORE SEQUENCING

 Library preparation and nanopore sequencing methods are described in detail in Supplemental Methods.

DATA ANALYSIS SOFTWARE

- Based on the previously described STRique software (15), we developed data analysis
- software to facilitate the identification of CGG repeat numbers and AGG interruptions for
- FXS carrier screening in our nanopore sequencing assay. The logic of software is described in
- detail in Suppmental Methods; the software code was licensed by Xiamen University and is
- available at https://github.com/guoqiwei-xmu/FXS-carrier-identifier.git.

TP-PCR ASSAY

samples were used as FXS carriers, and TP-PCR and CAFXS were used as methods for

comparison. As shown in Fig. 2, nanopore sequencing identified a wide range of expanded

alleles. AGG interruption patterns were identified in an allele-specific manner. A slight

discordance between nanopore sequencing and comparative method results was observed in

174 the reported CGG repeat numbers of expanded alleles (Table 1). Due to a one CGG repeat

175 difference between methods, the N1/P5 sample was designated as a non-carrier by the

nanopore sequencing assay but a carrier by comparative methods.

DETECTION OF FXS CARRIERS FROM WILDTYPE BACKGROUNDS WITH

THE MULTIPLEX NANOPORE SEQUENCING ASSAY

 We next evaluated whether the nanopore sequencing assay could examine multiple samples simultaneously and distinguish FXS carriers from wild-type backgrounds, as shown in Fig. 1. 181 Ten pairs of primers labeled with different identifier sequences were designed, validated, and used to amplify ten respective samples (Fig. 3A and Supplemental Table 2). As illustrated in Fig. 1, amplicons were pooled to achieve equal masses for library preparation and nanopore sequencing. Nanopore sequencing successfully detected a wide range of expanded alleles in the 10-plex assay (Fig. 3B-G). We assessed whether the nanopore sequencing assay could simultaneously examine more samples (e.g., 100 samples). Instead of using 100 identifier sequences to identify 100 different samples, we mimicked the scenario by decreasing the pooling proportion of the six target

amplicons to 6% (1% each), while increasing the pooling proportion of the four wild-type

190 amplicons to 94% (23.5% each). Similar to the results of the 10-plex assay, the 100-plex assay

successfully detected all expanded alleles within wild-type backgrounds (Fig. 3H-M).

INACCURATE BASE CALLING ATTRIBUTED TO VARIATIONS IN CGG REPEAT QUANTIFICATION

 Although the nanopore sequencing assay was able to detect various FXS carriers, the reported 195 CGG repeat numbers of expanded alleles differed slightly from those of the comparative methods (Table 1). Moreover, for a specific reference sample, the reported CGG repeat numbers ofthe expanded alleles were slightly discordant among the different nanopore 198 sequencing assays (Fig. 4A). To investigate the potential causes of these variations, we 199 manually examined the sequences of 20 random reads with fewer CGG repeats than those

passed through the nanopore than the longer amplicons of the expanded alleles. Two libraries

- 219 derived from reference samples, N1 (29 CGG repeats) and P5 (55 CGG repeats) were pooled
- 220 in equimolar amounts and sequenced. The read ratio of P5 to N1 was approximately 1.06,
- suggesting that there was no size preference for amplicons with different CGG repeats

 appropriate screening methods are urgently needed to implement such screening programs. A favorable testing method should be able to examine large-scale samples with high accuracy, low cost, short turnaround times, and ease of performance. Our nanopore sequencing assay would be one option that can meet these demands. First, we developed reliable and user-friendly software to facilitate sequencing data analysis and output results. Second, using reference and clinical samples, we demonstrated that the nanopore sequencing assay was able to identify the full range of premutation *FMR1* alleles, which account for the majority of FXS carriers, and the nanopore sequencing assay was able to reliably quantify CGG repeats and AGG interruptions, which are two important determinants for assessing the risk of full mutation expansion in carriers, thus facilitating genetic counseling for carrier screening. Third, using identifier sequences, we tested multiple samples in one assay, dramatically increasing test capacity and decreasing cost. In our 100-plex assay, the cost per sample was less than USD 10. Moreover, nanopore sequencing demonstrated no size preferences for amplicons with different CGG repeats, suggesting that the detection of expanded alleles will not be compromised by wild-type allele abundance as long as sufficient data are collected for each 259 sample, while tens of thousands of identifier sequences are available in the form of different 260 short combinations of nucleotides. In this regard, we could further increase sample capacity and decrease cost per sample by collecting more data using an advanced nanopore sequencing platform, such as PromethION. Fourth, the nanopore sequencing assay can be easily accomplished with a short turnaround time (for example, a 100-plex assay requires approximately two days) by a technician in a regular molecular diagnostics laboratory. Lastly, in comparison with TP-PCR and CAFXS, the equipment for nanopore sequencing assays is

 more available and portable, and thus could be more readily and widely adapted, particularly 267 in underdeveloped regions of the world (22) .

 In comparison with NGS or PacBio-based long-read sequencing, nanopore sequencing has a relatively higher sequencing error rate in single reads owing to inaccuracies in ionic current signal-to-nucleotide sequence translation (i.e., the base calling process) (22). This innate error would cause one to several copy number variations during quantification of CGG repeats in our nanopore assays, which may cause misclassification of subjects whose CGG repeat numbers are near the boundary between intermediate and premutation alleles. Technical limitation-associated variations in CGG repeat sizing are common to most methods and are allowed to a certain extent in technical standards (4). The accuracy of CGG repeat sizing can be improved, rendering it not a major concern in the use of our nanopore sequencing assay. For example, base calling is educable with machine learning models, and its accuracy continuously increases with the accumulation of nanopore sequencing data (23-25). Even at the current stage, a reference sample, such as N1/P5, can be used as a 280 quantitative control to monitor variation in base calling and direct the threshold setting for carrier identification.

 In comparison with amplification-free methods (15, 18), amplification of *FMR1* alleles drastically increases the sequencing depth of the target region and decreases costs. However, 284 owing to the high GC content of the target region and competitive effects of wild-type alleles, the amplification efficiencies of expanded alleles tend to decrease with increasing allelic expansion (4). In this study, carriers with a full range of premutation alleles were identified by our nanopore sequencing assay; however, carriers with full mutation alleles, which constitute

- 10.1111/cge.13075.
- 2. Lozano R, Azarang A, Wilaisakditipakorn T, Hagerman RJ. Fragile x syndrome: A review
- of clinical management. Intractable & Rare Diseases Research 2016;5:3:145-57 doi:
- 10.5582/irdr.2016.01048.
- 3. Pieretti M, Zhang F, Fu Y-H, Warren ST, Oostra BA, Caskey CT, et al. Absence of
- expression of the fmr-1 gene in fragile x syndrome. Cell 1991;66:4:817-22 doi:
- 10.1016/0092-8674(91)90125-i.
- 4. Spector E, Behlmann A, Kronquist K, Rose NC, Lyon E, Reddi HV. Laboratory testing for
- fragile x, 2021 revision: A technical standard of the american college of medical genetics
- and genomics (acmg). Genet Med 2021;23:5:799-812. Epub 20210401 doi:
- 10.1038/s41436-021-01115-y.
- 5. Committee opinion no. 691: Carrier screening for genetic conditions. Obstet Gynecol
- 2017;129:3:e41-e55. Epub 2017/02/23 doi: 10.1097/AOG.0000000000001952
- 00006250-201703000-00048 [pii].
- 6. Zlotogora J, Grotto I, Kaliner E, Gamzu R. The israeli national population program of
- genetic carrier screening for reproductive purposes. Genetics in Medicine 2016;18:2:203-6
- doi: 10.1038/gim.2015.55.
- 7. Westemeyer M, Saucier J, Wallace J, Prins SA, Shetty A, Malhotra M, et al. Clinical
- 328 experience with carrier screening in a general population: Support for a comprehensive
- pan-ethnic approach. Genetics in Medicine 2020;22:8:1320-8 doi:
- 10.1038/s41436-020-0807-4.
- 8. Archibald AD, Smith MJ, Burgess T, Scarff KL, Elliott J, Hunt CE, et al. Reproductive

genetic carrier screening for cystic fibrosis, fragile x syndrome, and spinal muscular

- reference panel for fragile x syndrome and its application to the screen of 10,000 chinese
- pregnant women and women planning pregnancy. Molecular Genetics & Genomic
- Medicine 2020;8:6 doi: 10.1002/mgg3.1236.
- 22. Ameur A, Kloosterman WP, Hestand MS. Single-molecule sequencing: Towards clinical
- applications. Trends in Biotechnology 2019;37:1:72-85 doi: 10.1016/j.tibtech.2018.07.013.
- 23. Singh G, Alser M, Denolf K, Firtina C, Khodamoradi A, Cavlak MB, et al. Rubicon: A
- framework for designing efficient deep learning-based genomic basecallers. Genome
- Biology 2024;25:1 doi: 10.1186/s13059-024-03181-2.
- 24. Amarasinghe SL, Su S, Dong X,Zappia L, Ritchie ME, Gouil Q. Opportunities and
- challenges in long-read sequencing data analysis.Genome Biology 2020;21:1 doi:
- 10.1186/s13059-020-1935-5.
- 25. Alser M, Lindegger J, Firtina C, Almadhoun N, Mao H, Singh G, et al. From molecules to
- genomic variations: Accelerating genome analysis via intelligent algorithms and
- architectures. Computational and Structural Biotechnology Journal 2022;20:4579-99 doi:
- 10.1016/j.csbj.2022.08.019.
- 26. Hantash FM, Goos DG, Tsao D, Quan F, Buller-Burckle A, Peng M, et al. Qualitative
- assessment of fmr1 (cgg)n triplet repeat status in normal, intermediate, premutation, full
- mutation, and mosaic carriers in both sexes: Implications for fragile x syndrome carrier and
- newborn screening. Genetics in Medicine 2010;12:3:162-73 doi:
- 10.1097/GIM.0b013e3181d0d40e.

396 **Figure 1. Flowchart of screen for fragile X syndrome carriers using our nanopore**

397 **sequencing assay.**

398 **Figure 2. Comparison of nanopore sequencing, TP-PCR, and CAFXS for detection of**

399 **different FXS carrier reference samples.**

Figure 3. Detection of FXS carriers within wildtype backgrounds with multiplex

- **nanopore sequencing assay.** (A) Efficacy of ten pairs of primers labeled with different
- identifier sequences was validated by amplification of wildtype samples. (B-G) CGG repeat
- numbers associated with reference samples in the 10-plex nanopore sequencing assay.
- (H-M) CGG repeat numbers associated with reference samples in the 100-plex nanopore
- sequencing assay.

versus their wildtype counterparts were similar between MinION and PromethION

platforms whose respective flow cells had 1190 and 8657 active nanopores.

418 Table 1. Comparison of nanopore sequencing, TP-PCR, and CAFXS for the detection of different FXS carrier reference samples.

420 **Table 2. Evaluation of nanopore sequencing assay with clinical samples**

421 * FXS carrier

Nanopore sequencing

AGG interruption pattern

CGG repeat number

CGG repeat number

B

A

E

 $50 -$

40

30

20

10

3

 $\overline{2}$

 $\overline{1}$

 $\mathbf 0$

